Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study.

MLA

Rousseau, Benoit, et al. “Impact of Trough Concentrations of Regorafenib and Its Major Metabolites M-2 and M-5 on Overall Survival of Chemorefractory Metastatic Colorectal Cancer Patients: Results from a Multicentre GERCOR TEXCAN Phase II Study.” European Journal of Cancer, vol. 168, June 2022, pp. 99–107. EBSCOhost, https://doi.org/10.1016/j.ejca.2022.03.009.

APA

Rousseau, B., Boukerma, A. K., Henriques, J., Cohen, R., Lucidarme, O., Borg, C., Tournigand, C., Kim, S., Bachet, J.-B., Mazard, T., Louvet, C., Chibaudel, B., Vernerey, D., Andre, T., & Hulin, A. (2022). Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study. European Journal of Cancer, 168, 99–107. https://doi.org/10.1016/j.ejca.2022.03.009

Chicago

Rousseau, Benoit, Arezki K. Boukerma, Julie Henriques, Romain Cohen, Olivier Lucidarme, Christophe Borg, Christophe Tournigand, et al. 2022. “Impact of Trough Concentrations of Regorafenib and Its Major Metabolites M-2 and M-5 on Overall Survival of Chemorefractory Metastatic Colorectal Cancer Patients: Results from a Multicentre GERCOR TEXCAN Phase II Study.” European Journal of Cancer 168 (June): 99–107. doi:10.1016/j.ejca.2022.03.009.